Company Genovis AB Nasdaq Stockholm

Equities

Medical Equipment, Supplies & Distribution

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Sector Diagnostic & Testing Substances

Inactive Instrument

End-of-day quote Nasdaq Stockholm Other stock markets
- ^SEK	-

Mar. 14	Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement	CI
Feb. 15	Genovis AB (publ.) Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

SEK in Million	2021	Weight	2022	Weight	Delta
Enzyme 83.1 %	93	100.0 %	85	83.1 %	-8.49%
Antibodies 16.9 %	-	-	17	16.9 %	-

SEK in Million	2021	Weight	2022	Weight	Delta
Rest of World 99.4 %	92	99.3 %	102	99.4 %	+10.15%
Sweden 0.6 %	1	0.7 %	1	0.6 %	-0.84%

Managers	Title	Age	Since
Fredrik Olsson CEO	Chief Executive Officer	53	01-12-31
Magnus Långberg DFI	Director of Finance/CFO	53	21-12-31
Rolf Lood CTO	Chief Tech/Sci/R&D Officer	40	16-12-31
Susanne Ahlberg IRC	Investor Relations Contact	67	06-12-31
Rikke Rytter SAM	Sales & Marketing	57	20-12-31
Jonathan Sjögren PRN	Corporate Officer/Principal	39	13-12-31

Members of the board	Title	Age	Since
Torben Vedel Stahl Jörgensen CHM	Chairman	72	20-05-04
Charlotta Ljungqvist BRD	Director/Board Member	63	18-12-31
Mikael Lönn BRD	Director/Board Member	75	13-12-31
Magnus Gustafsson BRD	Director/Board Member	52	21-12-31
Steve Jordan BRD	Director/Board Member	71	20-12-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	65,465,714	62,469,000 ( 95.42 %)	0	95.42 %

Name	Equities	%	Valuation
Mikael Lönn 14.50 %	9,490,653	14.50 %	30 M kr
Joh. Berenberg, Gossler & Co. KG (Investment Management) 6.158 %	4,031,662	6.158 %	13 M kr
Ålandsbanken Abp (Private Banking) 5.595 %	3,662,488	5.595 %	11 M kr
Swedbank Robur Fonder AB 4.735 %	3,100,000	4.735 %	10 M kr
Teknik Innovation Norden Fonder AB 4.310 %	2,821,296	4.310 %	9 M kr
Andra AP-fonden 3.407 %	2,230,304	3.407 %	7 M kr
Danske Bank A/S (Investment Management) 2.278 %	1,491,635	2.278 %	5 M kr
Aktia Fondbolag Ab 1.543 %	1,010,000	1.543 %	3 M kr
Aktia Bank Plc (Investment Management) 1.329 %	870,000	1.329 %	3 M kr
Lonvia Capital SASU 1.117 %	731,481	1.117 %	2 M kr

Genovis AB

Scheelevägen 2

220 07, Lund

+46 46 10 12 30

http://www.genovis.com

Healthcare

Healthcare Services

Healthcare Equipment & Supplies

Medical Equipment, Supplies & Distribution

Diagnostic & Testing Substances

	1st Jan change	Capi.
BIOMÉRIEUX	-0.60%	12.95B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-9.59%	7.84B
DIASORIN S.P.A.	+1.82%	5.5B
AUTOBIO DIAGNOSTICS CO., LTD.	+0.02%	4.61B
LANTHEUS HOLDINGS, INC.	+8.03%	4.61B
10X GENOMICS, INC.	-47.68%	3.4B
ANDON HEALTH CO., LTD.	+6.42%	2.66B
VITROLIFE AB	-14.59%	2.08B
MYRIAD GENETICS, INC.	+2.82%	1.79B

Diagnostic & Testing Substances